Long-Term follow-up of GH-treated girls with turner syndrome: Metabolic consequences

Hormone Research

Volumn 71, Issue 6, 2009, Pages 343-349

  Bannink, Ellen M N ^a   Van Der Palen, Roel L F ^a   Mulder, Paul G H ^b   De Muinck Keizer Schrama, Sabine M P F ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Growth hormone therapy, follow up; Homeostasis model assessment; Lipids; Turner syndrome

Indexed keywords

CHOLESTEROL; ESTRADIOL; GESTAGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HUMAN GROWTH HORMONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; NORDITROPIN SIMPLEX; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; BEDTIME DOSAGE; BODY HEIGHT; CARBOHYDRATE METABOLISM; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LONG TERM CARE; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; TURNER SYNDROME;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; LIPIDS; RECOMBINANT PROTEINS; TURNER SYNDROME;

EID: 66449127202     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000223419     Document Type: Article

References (26)

1. Wit JM, Massarano AA, Kamp GA, Hind- marsh PC, van Es A, Brook CG, et al: Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 1992;127: 7-12.
2. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, et al: Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88: 1119-1125.
3. Massa G, Heinrichs C, Verlinde S, Thomas M, Bourguignon JP, Craen M, et al: Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J Clin Endocrinol Metab 2003;88:4168- 4174.
4. Soriano-Guillen L, Coste J, Ecosse E, Leger J, Tauber M, Cabrol S, et al: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005;90: 5197-5204.
5. Turner H: A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938;23:566 -574.
6. Gravholt CH, Juul S, Naeraa RW, Hansen J: Morbidity in Turner syndrome. J Clin Epidemiol 1998;51:147-158.
7. Elsheikh M, Conway GS: The impact of obesity on cardiovascular risk factors in Turner's syndrome. Clin Endocrinol (Oxf) 1998; 49: 447-450.
8. Van Pareren YK, De Muinck Keizer-Schra- ma SM, Stijnen T, Sas TC, Drop SL: Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 2002; 87: 5442-5448.
9. Bannink EM, Raat H, Mulder PG, de Muinck Keizer-Schrama SM: Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pe- diatr 2006;148:95-101.
10. van den Berg J, Bannink EM, Wielopolski PA, Pattynama PM, de Muinck Keizer- Schrama SM, Helbing WA: Aortic distensi- bility and dimensions and the effects of growth hormone treatment in the Turner syndrome. Am J Cardiol 2006; 97: 1644-1649.
11. Bannink E, van der Palen R, Mulder P, de Muinck Keizer-Schrama S: Long-term follow-up of GH-treated girls with Turner syndrome: BMI, blood pressure, body proportions. Submitted 2008.
12. Matthews DR, Hosker JP, Rudenski AS, Nay-lor BA, Treacher DF, Turner RC: Homeosta- sis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Di- abetologia 1985;28:412-419.
13. Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192.
14. Bonora E, Targher G, Alberiche M, Bo- nadonna RC, Saggiani F, Zenere MB, et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
15. Uiterwaal CS, Witteman JC, de Bruijn AM, Hofman A, Grobbee DE: Families and natural history of lipids in childhood: an 18-year follow-up study. Am J Epidemiol 1997; 145: 777-785.
16. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL: Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab 2000;85:769-775.
17. Reaven GM, Moore J, Greenfield M: Quantification of insulin secretion and in vivo insulin action in nonobese and moderately obese individuals with normal glucose tolerance. Diabetes 1983;32:600-604.
18. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH: Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin En- docrinol Metab 1995;80:172-178.
19. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, et al: Insulin resistance: an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 1991; 72: 832-836.
20. Salgin B, Amin R, Yuen K, Williams RM, Murgatroyd P, Dunger DB: Insulin resistance is an intrinsic defect independent of fat mass in women with Turner's syndrome. Horm Res 2006; 65: 69-75.
21. Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, et al: Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004;89: 3516-3520.
22. Sagi L, Zuckerman-Levin N, Gawlik A, Ghizzoni L, Buyukgebiz A, Rakover Y, et al: Clinical significance of the parental origin of the X chromosome in turner syndrome. J Clin Endocrinol Metab 2007; 92:846-852.
23. Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S, Hara T: Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects. J Clin En-docrinol Metab 1998; 83: 3890-3896.
24. van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestation-al age. J Clin Endocrinol Metab 2003; 88: 347-353.
25. Gravholt CH, Christian Klausen I, Weeke J, Sandahl Christiansen J: Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethister- one. Atherosclerosis 2000;150:201-208.
26. Mauras N, Shulman D, Hsiang HY, Balago- pal P, Welch S: Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2007;92:4154-4160.